NanoCarrier Co Ltd - ESG Rating & Company Profile powered by AI
The ESG score covers 17 UN SDGs including: 'Quality Education', 'Reduced Inequalities' and 'Life below Water'. The analysis of NanoCarrier Co Ltd employs data from across the internet as well as from available disclosures by NanoCarrier Co Ltd. If you are employed by NanoCarrier Co Ltd and you wish to use your Sustainability aseessment, please contact us.
NanoCarrier Co Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.0; made up of an environmental score of 0.0, social score of 0.0 and governance score of 0.0.
0.0
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1967 | Hospira Inc | 0.3 | Low |
| 1967 | PRA Health Sciences Inc | 0.3 | Low |
| 1970 | NanoCarrier Co Ltd | 0.0 | Low |
| 1970 | CSPC Innovation Pharmaceutical Co Ltd | 0.0 | Low |
| 1970 | CTC Bio Inc | 0.0 | Low |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does NanoCarrier Co Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes NanoCarrier Co Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes NanoCarrier Co Ltd report the average age of the workforce?
Sign up for free to unlockDoes NanoCarrier Co Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes NanoCarrier Co Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes NanoCarrier Co Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes NanoCarrier Co Ltd offer flexible work?
Sign up for free to unlockDoes NanoCarrier Co Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes NanoCarrier Co Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes NanoCarrier Co Ltd conduct supply chain audits?
Sign up for free to unlockDoes NanoCarrier Co Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes NanoCarrier Co Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes NanoCarrier Co Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes NanoCarrier Co Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes NanoCarrier Co Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes NanoCarrier Co Ltd disclose water use targets?
Sign up for free to unlockDoes NanoCarrier Co Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid NanoCarrier Co Ltd have a product recall in the last two years?
Sign up for free to unlockDoes NanoCarrier Co Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes NanoCarrier Co Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas NanoCarrier Co Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes NanoCarrier Co Ltd disclose parental leave metrics?
Sign up for free to unlockDoes NanoCarrier Co Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes NanoCarrier Co Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes NanoCarrier Co Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes NanoCarrier Co Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes NanoCarrier Co Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes NanoCarrier Co Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs NanoCarrier Co Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes NanoCarrier Co Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes NanoCarrier Co Ltd disclose its waste policy?
Sign up for free to unlockDoes NanoCarrier Co Ltd report according to TCFD requirements?
Sign up for free to unlockDoes NanoCarrier Co Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes NanoCarrier Co Ltd disclose energy use targets?
Sign up for free to unlockDoes NanoCarrier Co Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes NanoCarrier Co Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for NanoCarrier Co Ltd
These potential risks are based on the size, segment and geographies of the company.
NanoCarrier Co., Ltd. researches, develops, produces, and sells pharmaceuticals using micelle nanoparticle technology primarily for the treatment of cancer in Japan. The company's product pipeline includes VB-111 non-proliferative adenovirus vector, which is in phase III clinical trials for the treatment of ovarian cancer, as well as in phase II clinical trials for treatment of rGBM and colorectal cancer; ENT103 Otolaryngology product that is in phase III clinical trials for the treatment of otitis media; NC-6004 Cisplatin micelle, which is in phase II clinical trials for the treatment of head and neck cancer; NC-6300 Epirubicin micelle that is in phase I clinical trials for the treatment of hemangiosarcoma; and NC-6100 PRDM14 (siRNA), which is in phase I clinical trials for the treatment of breast cancer. Its product pipeline also comprises TUG1 (ASO) for glioblastoma and RUNX1 (mRNA) for osteoarthritis of the knee that are in preclinical stage. The company was founded in 1996 and is headquartered in Tokyo, Japan.